Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06103201 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
A Phase 1 study of Traumatic Brain Injury and Subarachnoid Hemorrhage, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06103201: Recruiting Phase 1 study of Traumatic Brain Injury and Subarachnoid Hemorrhage, sponsored by University of Maryland, Baltimore.
NCT06103201 is a Phase 1 study of Traumatic Brain Injury and Subarachnoid Hemorrhage that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 15 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06103201, a Phase 1 study of Traumatic Brain Injury and Subarachnoid Hemorrhage, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI. The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).
Primary Outcome
To assess the differences between the three patient groups
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
Study Locations (1)
Maryland
- University of Maryland Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2027-11-26 |
| Phase | Phase 1 |
What NCT06103201 shows while recruiting
NCT06103201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT06103201 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06103201 about?
NCT06103201 is a clinical study titled "Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury". The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived me...
What is the current status of trial NCT06103201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-10-26. Estimated completion is 2027-11-26.
What conditions does trial NCT06103201 study?
This clinical trial studies the following conditions: Traumatic Brain Injury, Subarachnoid Hemorrhage.
What interventions are being tested in trial NCT06103201?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG).
Who is sponsoring clinical trial NCT06103201?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06103201 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06103201's enrollment target sits among peer trials
15 156th of 171 higher than 12 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
RECRUITING · Phase 1
-
Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain Injury
RECRUITING · Phase 1
-
Traumatic Brain Injury Peripheral Nerve Study
COMPLETED · Phase 1
-
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
COMPLETED · Phase 1
-
Functional Connectivity as a Biomarker of rTMS
COMPLETED · Phase 1
-
Effects of TT301 on Cytokine Levels Post Endotoxin Challenge
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI